Brief: Paladin Phase 4 Study Confirms Iluvien® Patients' Reduced Need For Multiple Treatments
06/10/2022 13:32
Oct 6 (Reuters) - Alimera Sciences Inc ALIM.O :
* PALADIN PHASE 4 STUDY CONFIRMS ILUVIEN® PATIENTS' REDUCED
NEED
FOR MULTIPLE TREATMENTS
Source text for Eikon: ID:nGNX6Hr4Xs
Further company coverage: ALIM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger